Zydus Cadila cancer drug Ibrutinib secures USFDA nod
For Ibrutinib Capsules, 140 mg, the company will have 180-days of shared generic drug exclusivity.
Ahmedabad: Drugmaker, Zydus Cadila, today announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Ibrutinib Capsules, 70 mg and 140 mg (US RLD: Imbruvica Capsules).
Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.
According to the USFDA letter, Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg. Therefore, with this approval, Zydus is eligible for 180 days of generic drug exclusivity for Ibrutinib Capsules, 70 mg.
For Ibrutinib Capsules, 140 mg, the company will have 180-days of shared generic drug exclusivity. The 70 mg capsule has brand sales of USD 32.5 mn, while the 140 mg dose has brand sales of USD 745.9 mn. Zydus is the first company to receive approval for generic Ibrutinib 70 mg capsules.
Managing Director, Zydus Group, Dr Sharvil Patel commented, "This FDA approval of Ibrutinib Capsules reinforces our long-term commitment to provide patients and caregivers access to affordable therapies. We have been investing significantly in building a portfolio of complex generic products and leveraging capabilities that will help us successfully commercialize and gain meaningful market share in the complex generic products and difficult-to-manufacture generic products. We have created a diversified portfolio of over 50 filed complex ANDAs seeking USFDA approval and we will continue to expand this as we explore opportunities to grow our US business in 2021 and beyond."
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.